drugset

drugset / Trial / NCT00041639

Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer

NCT00041639 ↗

Phase 1/2 Completed 75 enrolled Gilead Sciences

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of pancreatic cancer.

Timeline

Start: 2000-01
Primary completion: —
Completion: 2003-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	labetuzumab	Monoclonal antibody	—	—

Indications